Li 2010.

Methods	Participants were not receiving lipid‐altering agents, so no wash‐out was required 12‐Week before‐and‐after trial
Participants	84 men and women with CHD aged 55 to 76 years Exclusion criteria: liver or renal failure, diabetes mellitus, MI, HTN, severe or unstable angina pectoris, heart failure, severe cardiac arrhythmia, transplantation Atorvastatin 10 mg/d baseline TC: 5.43 mmol/L (210 mg/dL) Atorvastatin 10 mg/d baseline LDL‐C: 3.31 mmol/L (128 mg/dL) Atorvastatin 10 mg/d baseline HDL‐C: 1.13 mmol/L (44 mg/dL) Atorvastatin 10 mg/d baseline TG: 1.68 mmol/L (149 mg/dL)
Interventions	Atorvastatin 10 mg/d Simvastatin 20 mg/d
Outcomes	Per cent change from baseline at 12 weeks of serum TC, LDL‐C, HDL‐C and TG
Notes	Atorvastatin group was analysed
Risk of bias
Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	Atorvastatin 10 mg/d; intervention was analysed, and as no placebo group was included for comparison, assessment of random sequence generation is not applicable
Allocation concealment (selection bias)	Unclear risk	Atorvastatin 10 mg/d; intervention was analysed, and as no placebo group was included for comparison, assessment of allocation concealment is not applicable
Blinding (performance bias and detection bias) All outcomes	Unclear risk	Atorvastatin 10 mg/d; intervention was analysed, and as no placebo group was included for comparison, blinding status is not applicable
Incomplete outcome data (attrition bias) All outcomes	Low risk	All participants were included in the efficacy analysis
Selective reporting (reporting bias)	Low risk	All lipid parameters were measured
Other bias	Low risk	The study appears to be free of other sources of bias